

Medical drug benefit *Clinical Criteria* updates

On August 20, 2021, the Pharmacy and Therapeutics (P&T) Committee approved the following *Clinical Criteria* applicable to the **medical drug benefit** for Anthem Blue Cross. These policies were developed, revised, or reviewed to support clinical coding edits.

Visit [Clinical Criteria](#) to search for specific policies. If you have questions or would like additional information, use this [email](#).

Please see the explanation/definition for each category of *Clinical Criteria* below:

- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) denote that the criteria may be perceived as more restrictive

Please share this notice with other members of your practice and office staff.

Note: The *Clinical Criteria* listed below applies only to the medical drug benefits contained within the member's medical policy. This does not apply to pharmacy services.

Effective date	Document number	<i>Clinical Criteria</i> title	New or revised
January 22, 2022	ING-CC-0202*	Saphnelo (anifrolumab-fnia)	New
January 22, 2022	ING-CC-0203*	Ryplazim (plasminogen, human-tvmh)	New
January 22, 2022	ING-CC-0010*	Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors	Revised
January 22, 2022	ING-CC-0034*	Hereditary Angioedema Agents	Revised
January 22, 2022	ING-CC-0027*	Denosumab Agents	Revised
January 22, 2022	ING-CC-0001*	Erythropoiesis Stimulating Agents	Revised
January 22, 2022	ING-CC-0156*	Reblozyl (luspaterecept)	Revised
January 22, 2022	ING-CC-0124	Keytruda (pembrolizumab)	Revised
January 22, 2022	ING-CC-0104*	Levoleucovorin Agents	Revised
January 22, 2022	ING-CC-0062	Tumor Necrosis Factor Antagonists	Revised
January 22, 2022	ING-CC-0009*	Lemtrada (alemtuzumab) for the Treatment of Multiple Sclerosis	Revised
January 22, 2022	ING-CC-0020	Tysabri (natalizumab)	Revised
January 22, 2022	ING-CC-0029*	Dupilixent (dupilumab)	Revised
January 22, 2022	ING-CC-0038	Human Parathyroid Hormone Agents	Revised
January 22, 2022	ING-CC-0182*	Iron Agents	Revised
January 22, 2022	ING-CC-0075	Rituximab Agents for Non-Oncologic Indications	Revised
January 22, 2022	ING-CC-0096	Asparagine Specific Enzymes	Revised
January 22, 2022	ING-CC-0169	Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)	Revised

<https://providers.anthem.com/ca>

Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County.
ACA-NU-0383-21 October 2021

Effective date	Document number	<i>Clinical Criteria</i> title	New or revised
January 22, 2022	ING-CC-0193	Evkeeza (evinacumab)	Revised
January 22, 2022	ING-CC-0081*	Crysvita (burosumab-twza)	Revised



Email is the quickest and most direct way to receive important information from Anthem Blue Cross.

To start receiving email from us (including some sent in lieu of fax or mail), submit your information using the QR code to the right or via our online form (<https://bit.ly/3ILgko8>).

